美国立体定向体部放射治疗用于转移性肾细胞癌治疗的时间趋势及预测因素
Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S.
作者信息
Paciotti Marco, Schmidt Andrew L, Ravi Praful, McKay Rana R, Trinh Quoc-Dien, Choueiri Toni K
机构信息
Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Department of Urology, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.
出版信息
Oncologist. 2021 May;26(5):e905-e906. doi: 10.1002/onco.13736. Epub 2021 Mar 24.
Abstract
This letter to the editor outlines the use of stereotactic body radiotherapy for metastatic renal cell carcinoma in the U.S., identifying clinical predictors of utilization using the National Cancer Database.
摘要
这封致编辑的信概述了美国立体定向体部放疗在转移性肾细胞癌中的应用，并利用国家癌症数据库确定了使用情况的临床预测因素。
相似文献
1
Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S.美国立体定向体部放射治疗用于转移性肾细胞癌治疗的时间趋势及预测因素
Oncologist. 2021 May;26(5):e905-e906. doi: 10.1002/onco.13736. Epub 2021 Mar 24.
2
Current Role of Radiotherapy for Renal-Cell Carcinoma: Review.放射治疗在肾细胞癌中的当前作用：综述
Clin Genitourin Cancer. 2017 Apr;15(2):183-187. doi: 10.1016/j.clgc.2016.09.004. Epub 2016 Sep 19.
3
Stereotactic ablative radiotherapy for primary kidney cancer.原发性肾癌的立体定向消融放疗
Lancet Oncol. 2024 Jun;25(6):e229. doi: 10.1016/S1470-2045(24)00252-3.
4
Stereotactic ablative radiotherapy for primary kidney cancer.原发性肾癌的立体定向消融放疗
Lancet Oncol. 2024 Jun;25(6):e228. doi: 10.1016/S1470-2045(24)00181-5.
5
Renal-cell carcinoma.肾细胞癌
N Engl J Med. 2006 Mar 9;354(10):1095-6; author reply 1095-6. doi: 10.1056/NEJMc053645.
6
Stereotactic ablative radiotherapy for primary kidney cancer - Authors' reply.原发性肾癌的立体定向消融放疗——作者回复
Lancet Oncol. 2024 Jun;25(6):e230. doi: 10.1016/S1470-2045(24)00276-6.
7
The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer.放疗在肾癌综合管理中的重新引入。
Cancer J. 2020 Sep/Oct;26(5):448-459. doi: 10.1097/PPO.0000000000000475.
8
Stereotactic Ablative Body Radiotherapy: An Emerging Weapon in the Treatment Armamentarium for Renal Cell Carcinoma or a Potential Avenue for Overtreatment?立体定向消融体部放疗：肾细胞癌治疗手段中的新兴武器还是过度治疗的潜在途径？
Eur Urol. 2022 Dec;82(6):623-624. doi: 10.1016/j.eururo.2022.07.020. Epub 2022 Aug 6.
9
Durable control of locally recurrent renal cell carcinoma using stereotactic body radiotherapy.使用立体定向体部放疗对局部复发性肾细胞癌进行持久控制。
BMJ Case Rep. 2014 Sep 8;2014:bcr2014206015. doi: 10.1136/bcr-2014-206015.
10
Stereotactic body radiation therapy (SBRT): A new treatment option in renal cancer.立体定向体部放射治疗（SBRT）：肾癌的一种新治疗选择。
Actas Urol Esp (Engl Ed). 2024 May;48(4):260-261. doi: 10.1016/j.acuroe.2023.11.007. Epub 2023 Nov 18.
引用本文的文献
1
Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell Carcinoma.立体定向放射治疗用于治疗肾细胞癌腺性转移灶
Adv Radiat Oncol. 2025 Jun 13;10(9):101835. doi: 10.1016/j.adro.2025.101835. eCollection 2025 Sep.
2
Stereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know.泌尿外科癌症的立体定向体部放疗——泌尿外科医生需要了解的内容
Life (Basel). 2024 Dec 19;14(12):1683. doi: 10.3390/life14121683.
3
Active Surveillance in Metastatic Renal Cell Carcinoma.转移性肾细胞癌的主动监测
J Kidney Cancer VHL. 2024 Jun 4;11(2):27-38. doi: 10.15586/jkcvhl.v11i2.309. eCollection 2024.
4
Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.将立体定向消融放疗纳入肾细胞癌的多学科综合管理。
Curr Oncol. 2023 Dec 1;30(12):10283-10298. doi: 10.3390/curroncol30120749.
5
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma.转移性肾细胞癌患者循环肿瘤细胞的纵向分子谱分析。
J Clin Oncol. 2022 Nov 1;40(31):3633-3641. doi: 10.1200/JCO.22.00219. Epub 2022 May 26.
6
Identification of a Somatic Mutation-Derived Long Non-Coding RNA Signatures of Genomic Instability in Renal Cell Carcinoma.肾细胞癌中基因组不稳定的体细胞突变衍生长链非编码RNA特征的鉴定
Front Oncol. 2021 Oct 5;11:728181. doi: 10.3389/fonc.2021.728181. eCollection 2021.
7
Trend in Stereotactic Radiation Therapy Use for Management of Bone and Brain Metastases in Patients with Renal Cell Carcinoma in Australia.澳大利亚肾细胞癌患者骨和脑转移立体定向放疗使用趋势。
Oncologist. 2021 Jul;26(7):e1288-e1289. doi: 10.1002/onco.13792. Epub 2021 Apr 28.
本文引用的文献
1
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.寡转移癌症患者立体定向消融放疗与标准姑息治疗的比较（SABR-COMET）：一项随机、2 期、开放标签试验。
Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11.
2
Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities.立体定向体部放射治疗的免疫调节作用：临床前见解与临床机遇
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):35-52. doi: 10.1016/j.ijrobp.2019.02.046. Epub 2019 Mar 2.
3
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.舒尼替尼治疗同步转移性肾细胞癌患者中即刻与延迟细胞减瘤性肾切除术的比较：SURTIME 随机临床试验。
JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543.
4
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.舒尼替尼单药治疗或肾细胞癌转移患者肾切除术后的治疗。
N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.
5
Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review.立体定向放射治疗颅内外转移性肾细胞癌的疗效：一项系统评价。
Acta Oncol. 2015 Feb;54(2):148-57. doi: 10.3109/0284186X.2014.939298. Epub 2014 Aug 20.
Zotero 插件